Sol-Gel Technologies is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Co.'s primary product candidate, Twyneo®, is a once-daily, non-antibiotic topical cream that it is developing for the treatment of acne vulgaris. Co.'s second branded product candidate is Epsolay®, a potential treatment for subtype II rosacea. Co.'s other branded product candidates are SGT-210, a potential treatment of palmoplantar keratoderma. Co. is also pre-clinically testing erlotinib, tapinarof and roflumilast in various new pharmaceutical indications. The SLGL average annual return since 2018 is shown above.
The Average Annual Return on the SLGL average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SLGL average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SLGL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|